Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-05
2005-04-05
Nguyen, Dave T. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S023510, C536S023520, C536S023700, C435S320100, C435S455000, C435S458000, C435S078000, C568S624000
Reexamination Certificate
active
06875748
ABSTRACT:
The present invention relates to pharmaceutical compositions and methods to improve expression of exogenous polypeptides into vertebrate cells in vivo, utilizing delivery of polynucleotides encoding such polypeptides. More particularly, the present invention provides the use of salts, in particular sodium and potassium salts of phosphate, in aqueous solution, and auxiliary agents, in particular detergents and surfactants, in pharmaceutical compositions and methods useful for direct polynucleotide-based polypeptide delivery into the cells of vertebrates.
REFERENCES:
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5470568 (1995-11-01), Lee
patent: 5552309 (1996-09-01), March
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5641665 (1997-06-01), Hobart et al.
patent: 5656611 (1997-08-01), Kabanov et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5861397 (1999-01-01), Wheeler
patent: 5883103 (1999-03-01), Burnside et al.
patent: 5885590 (1999-03-01), Hunter et al.
patent: 5897876 (1999-04-01), Rudnic et al.
patent: 5910488 (1999-06-01), Nabel et al.
patent: 5952004 (1999-09-01), Rudnic et al.
patent: 5962428 (1999-10-01), Carrano et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 5994314 (1999-11-01), Eljamal et al.
patent: 5994317 (1999-11-01), Wheeler
patent: 6022874 (2000-02-01), Wheeler
patent: 6040295 (2000-03-01), Rolland et al.
patent: 6086899 (2000-07-01), Balasubramanian et al.
patent: 6120794 (2000-09-01), Liu et al.
patent: 6147055 (2000-11-01), Hobart et al.
patent: 6149922 (2000-11-01), Balasubramanian et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6221959 (2001-04-01), Kabanov et al.
patent: 6228844 (2001-05-01), Wolff et al.
patent: 6353055 (2002-03-01), Kabanov et al.
patent: 6359054 (2002-03-01), Lemieux et al.
patent: 6399588 (2002-06-01), Hobart et al.
patent: 6416947 (2002-07-01), Balasubramanian et al.
patent: 6440743 (2002-08-01), Kabanov et al.
patent: 6586409 (2003-07-01), Wheeler
patent: 6670332 (2003-12-01), Wheeler
patent: 6696424 (2004-02-01), Wheeler
patent: 20030032615 (2003-02-01), Fegner et al.
patent: 20030186913 (2003-10-01), Wolff et al.
patent: 20030191082 (2003-10-01), Wheeler
patent: 20030203863 (2003-10-01), Hobart et al.
patent: 20040157789 (2004-08-01), Geall
patent: 737720 (1998-08-01), None
patent: 2 284 399 (2000-03-01), None
patent: WO 9510265 (1995-04-01), None
patent: WO 9621470 (1996-07-01), None
patent: WO 9730731 (1997-08-01), None
patent: WO 9926663 (1999-06-01), None
patent: WO 9931262 (1999-06-01), None
patent: WO 9964615 (1999-12-01), None
patent: WO 0057917 (2000-03-01), None
patent: WO 0040273 (2000-07-01), None
patent: WO 0040273 (2000-07-01), None
patent: WO 0109303 (2001-02-01), None
patent: WO 0165911 (2001-09-01), None
patent: WO 0183698 (2001-11-01), None
patent: WO 0187234 (2001-11-01), None
patent: WO 0200844 (2002-01-01), None
Norihisa Ishii et al., AIDS Research and Human Retroviruses, vol. 13, No. 16, 1997, pp. 1421-1428.*
Jeffrey B. Ulmer et al., Science, vol. 259, Mar. 19, 1993, pp. 1745-1749.*
No Author Listed, “Nomenclature and the Pluronic® Surfactant Grid,” <<http://www.basf.com/static/OpenMarket/Xcelerate/Preview_cid-982931199731_pubid -974236729499_c-Article.html>>, accessed Dec. 16, 2002.
Schmolka, I.R., “A Review of Block Polymer Surfactants,”J. Am. Oil Chem. Soc. 54:110-116, The American Oil Chemist's Society (1977).
Adams-Graves et al., “RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study,”Blood 90:2041-2046, American Society for Hematology, W. B. Saunders Co. (1997).
Anwer, K. et al., “Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines,”Pharm. Res. 16:889-895, American Associated of Pharmaceutical Scientists (Jun. 1999).
Baranov, A. et al., “Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres,”Gene Ther. 6:1406-1414, Stockton Press (Aug. 1999).
Bertling, W.M. et al., “Use of liposomes, viral capsids, and nanoparticle as DNA carriers,”Biotechnol. Appl. Biochm. 13:390-405, Portland Press Limited (1991).
Boussif, O. et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine,”Proc. Natl. Acad. Sci. USA 92:7297-7301, National Academy of Sciences (1995).
Cho, C.-W. et al., “Improvement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent,”Biotechnol. Appl. Biochem. 32:21-26, Portland Press Limited (Aug. 2000).
Doh, S.G. et al., “Spatial-temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA,”Gene Ther. 4:648-663, Stockton Press (1997).
Freeman, D.J. and Niven, R.W., “The influence of sodium glycocholate and other additives on the in vivo transfection of plasmid DNA in the lungs,”Pharm. Res. 13:202-209, American Association of Pharmaceutical Scientists (1996).
Kariko, K. et al., “Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA,”Biochim. Biophys. Acta. 1369:320-334, Elsevier Science Ltd. (1998).
Kichler, A. et al., “Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles,”Gene Ther. 5:855-860, Stockton Press (1998).
Lee, R. et al., “Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo,”Proc. Natl. Acad. Sci. U.S.A. 89:4524-4528, National Academy of Sciences (1992).
Lemieux, P. et al., “A Combination of Poloxamers Increases and Prolongs Gene Expression of Plasmid DNA in Skeletal Muscle,” Abstracts Presented at the Seventh Meeting of the European Society of Gene Therapy. Munich, Germany, Nov. 26-28 1999.
Lemieux, P. et al., “A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle,”Gene Ther.7:986-991, Stockton Press (Jun. 2000).
Leong, K.W. et al., “DNA-polycation nanospheres as non-viral gene delivery vehicles,”J. Control. Release 53:183-93, Elsevier Science B.V. (1998).
Liu, F. et al., “Effect of Non-Ionic Surfactants on the Formation of DNA/Emulsion Complexes and Emulsion-Mediated Gene Transfer,”Pharmaceutical Research 13:1642-1646, Plenum Publishing Corporation (1996).
Lunsford, L. et al., “Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle,”J. Drug Target. 8:39-50, Gordon and Breach Publishing Group (Nov. 2000).
Mumper, R.J. et al., “Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle,”J. Control. Release 52:191-203, Elsevier Science B.V. (1998).
Mumper, R.J et al., “Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle,”Pharm. Res. 13:701-709, American Association of Pharmaceutical Scientists (1996).
O'Keefe et al., “Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for actute myocardial infarction,”Am. J. Cardiol. 78:747-750, Elsevier Science Ltd. (1996).
Orson, F.M. et al., “Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses,”J. Immunol. 164:6313-6321, American Association of Immunologists (Jun. 2000).
Raczka, E. et al., “The effect of synthetic surfactant Exosurf on gene transfer in mouse lung in vivo,”Gene Ther. 5:1333-1339, Stockton Press (1998).
Sawa, T. et al., “Intraluminal water increases expression of plasmid DNA in rat lung,”Hum. Gene. Ther. 7:933-941, Mary Ann Liebert, Inc. (1996).
Shi, N.Y.
Hartikka Jukka
Manthorpe Marston
Meek Jennifer
Sukhu Loretta
Nguyen Dave T.
Schnizer Richard
Sterne Kessler Goldstein & Fox P.L.L.C.
Vical Incorporated
LandOfFree
Compositions and methods for in vivo delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for in vivo delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for in vivo delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3421122